- Home
- UL vs REGN Comparison
UL vs REGN Comparison
Compare UL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UL
- REGN
- Stock Information
- Founded
- UL 1930
- REGN 1988
- Country
- UL United Kingdom
- REGN United States
- Employees
- UL N/A
- REGN N/A
- Industry
- UL Package Goods/Cosmetics
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- UL Consumer Discretionary
- REGN Health Care
- Exchange
- UL Nasdaq
- REGN Nasdaq
- Market Cap
- UL 136.3B
- REGN 110.0B
- IPO Year
- UL N/A
- REGN 1991
- Fundamental
- Price
- UL $55.68
- REGN $681.58
- Analyst Decision
- UL Buy
- REGN Buy
- Analyst Count
- UL 5
- REGN 25
- Target Price
- UL $60.00
- REGN $1,024.28
- AVG Volume (30 Days)
- UL 2.5M
- REGN 857.0K
- Earning Date
- UL 02-06-2025
- REGN 02-04-2025
- Dividend Yield
- UL 3.42%
- REGN N/A
- EPS Growth
- UL N/A
- REGN 15.31
- EPS
- UL 2.82
- REGN 40.43
- Revenue
- UL $64,601,950,064.00
- REGN $13,847,100,000.00
- Revenue This Year
- UL $2.91
- REGN $10.24
- Revenue Next Year
- UL $3.40
- REGN $4.30
- P/E Ratio
- UL $19.46
- REGN $16.86
- Revenue Growth
- UL N/A
- REGN 5.72
- 52 Week Low
- UL $46.46
- REGN $666.25
- 52 Week High
- UL $65.87
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- UL 38.68
- REGN 36.27
- Support Level
- UL $54.60
- REGN $666.25
- Resistance Level
- UL $56.43
- REGN $743.28
- Average True Range (ATR)
- UL 0.59
- REGN 19.76
- MACD
- UL -0.02
- REGN 0.45
- Stochastic Oscillator
- UL 35.25
- REGN 19.90
About UL Unilever PLC
Unilever is a diversified personal-care (52% of 2022 sales by value), homecare (14%), and packaged food (34%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Axe and Dove skin products, and the TRESemmé haircare brand. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, Garancia, and The Vegetarian Butcher.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).